Intervention Review

You have free access to this content

Oral deferiprone for iron chelation in people with thalassaemia

  1. Sheila A Fisher1,
  2. Susan J Brunskill1,
  3. Carolyn Doree1,
  4. Onima Chowdhury2,
  5. Sarah Gooding3,
  6. David J Roberts1,*

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 21 AUG 2013

Assessed as up-to-date: 7 AUG 2013

DOI: 10.1002/14651858.CD004839.pub3


How to Cite

Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD004839. DOI: 10.1002/14651858.CD004839.pub3.

Author Information

  1. 1

    NHS Blood and Transplant, Systematic Review Initiative, Oxford, Oxon, UK

  2. 2

    Weatherall Institute of Molecular Medicine, Haematopoietic Stem Cell Laboratory, Oxford, UK

  3. 3

    John Radcliffe and Churchill Hospital, Department of Haematology, Oxford, UK

*David J Roberts, Systematic Review Initiative, NHS Blood and Transplant, Level 2, John Radcliffe Hospital, Headington, Oxford, Oxon, OX3 9BQ, UK. david.roberts@ndcls.ox.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 AUG 2013

SEARCH

[Figure 1]
Figure 1. PRISMA study flow diagram.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Forest plot of comparison: 1 Deferiprone alone versus DFO alone, outcome: 1.14 Adverse events.
[Figure 4]
Figure 4. Forest plot of comparison: 3 Deferiprone and DFO in combination versus DFO alone, outcome: 3.11 Adverse events.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Deferiprone alone versus DFO alone, Outcome 1 Left ventricular ejection fraction: mean change from baseline (%).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Deferiprone alone versus DFO alone, Outcome 2 Right ventricular ejection fraction: mean at endpoint (%).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Deferiprone alone versus DFO alone, Outcome 3 Liver fibrosis Ishak score: mean at endpoint.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Deferiprone alone versus DFO alone, Outcome 4 Serum ferritin concentration: mean change from baseline (ng/ml).
[Analysis 1.5]
Analysis 1.5. Comparison 1 Deferiprone alone versus DFO alone, Outcome 5 Urinary iron excretion: mean at endpoint (mg/24h).
[Analysis 1.6]
Analysis 1.6. Comparison 1 Deferiprone alone versus DFO alone, Outcome 6 Urinary iron excretion: mean over study (%).
[Analysis 1.7]
Analysis 1.7. Comparison 1 Deferiprone alone versus DFO alone, Outcome 7 Urinary iron excretion: mean change from baseline (mg/24h).
[Analysis 1.8]
Analysis 1.8. Comparison 1 Deferiprone alone versus DFO alone, Outcome 8 Liver iron concentration: ratio of geometric means at endpoint (mg/g dry weight).
[Analysis 1.9]
Analysis 1.9. Comparison 1 Deferiprone alone versus DFO alone, Outcome 9 Liver iron concentration: mean change from baseline (mg/g dry weight).
[Analysis 1.10]
Analysis 1.10. Comparison 1 Deferiprone alone versus DFO alone, Outcome 10 Myocardial T2*: ratio of geometric means of change from baseline.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Deferiprone alone versus DFO alone, Outcome 11 Chelation efficiency (%).
[Analysis 1.12]
Analysis 1.12. Comparison 1 Deferiprone alone versus DFO alone, Outcome 12 Plasma NTBI: mean change from baseline (mM).
[Analysis 1.13]
Analysis 1.13. Comparison 1 Deferiprone alone versus DFO alone, Outcome 13 Total iron excretion: mean at endpoint (mg/kg/day).
[Analysis 1.14]
Analysis 1.14. Comparison 1 Deferiprone alone versus DFO alone, Outcome 14 Adverse events.
[Analysis 1.15]
Analysis 1.15. Comparison 1 Deferiprone alone versus DFO alone, Outcome 15 Participant compliance (%).
[Analysis 2.1]
Analysis 2.1. Comparison 2 Deferiprone alone versus deferiprone and DFO in combination, Outcome 1 Left ventricular ejection fraction: mean at endpoint (%).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Deferiprone alone versus deferiprone and DFO in combination, Outcome 2 Serum ferritin concentration: mean at endpoint (ng/ml).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Deferiprone alone versus deferiprone and DFO in combination, Outcome 3 Serum ferritin concentration: mean change from baseline (ng/ml).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Deferiprone alone versus deferiprone and DFO in combination, Outcome 4 Urinary iron excretion: mean over study (%).
[Analysis 2.5]
Analysis 2.5. Comparison 2 Deferiprone alone versus deferiprone and DFO in combination, Outcome 5 Urinary iron excretion: mean at endpoint (mg/24h).
[Analysis 2.6]
Analysis 2.6. Comparison 2 Deferiprone alone versus deferiprone and DFO in combination, Outcome 6 Liver iron concentration: mean at endpoint (mg/g dry weight).
[Analysis 2.7]
Analysis 2.7. Comparison 2 Deferiprone alone versus deferiprone and DFO in combination, Outcome 7 Chelation efficiency (%).
[Analysis 2.8]
Analysis 2.8. Comparison 2 Deferiprone alone versus deferiprone and DFO in combination, Outcome 8 Plasma NTBI: mean change from baseline (mM).
[Analysis 2.9]
Analysis 2.9. Comparison 2 Deferiprone alone versus deferiprone and DFO in combination, Outcome 9 Total Iron excretion: mean at endpoint (mg/kg/day).
[Analysis 2.10]
Analysis 2.10. Comparison 2 Deferiprone alone versus deferiprone and DFO in combination, Outcome 10 Adverse Events.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Deferiprone and DFO in combination versus DFO alone, Outcome 1 Left ventricular ejection fraction: mean at endpoint (%).
[Analysis 3.2]
Analysis 3.2. Comparison 3 Deferiprone and DFO in combination versus DFO alone, Outcome 2 Serum ferritin concentration: ratio of geometric means at endpoint (ng/ml).
[Analysis 3.3]
Analysis 3.3. Comparison 3 Deferiprone and DFO in combination versus DFO alone, Outcome 3 Serum ferritin concentration: ratio of geometric means at endpoint (ng/ml).
[Analysis 3.4]
Analysis 3.4. Comparison 3 Deferiprone and DFO in combination versus DFO alone, Outcome 4 Serum ferritin concentration: mean change from baseline (ng/ml).
[Analysis 3.5]
Analysis 3.5. Comparison 3 Deferiprone and DFO in combination versus DFO alone, Outcome 5 Urinary iron excretion: mean at endpoint (mg/24h).
[Analysis 3.6]
Analysis 3.6. Comparison 3 Deferiprone and DFO in combination versus DFO alone, Outcome 6 Urinary iron excretion: mean over study (%).
[Analysis 3.7]
Analysis 3.7. Comparison 3 Deferiprone and DFO in combination versus DFO alone, Outcome 7 Liver iron concentration: mean change from baseline.
[Analysis 3.8]
Analysis 3.8. Comparison 3 Deferiprone and DFO in combination versus DFO alone, Outcome 8 Chelation efficiency (%).
[Analysis 3.9]
Analysis 3.9. Comparison 3 Deferiprone and DFO in combination versus DFO alone, Outcome 9 Plasma NBTI: mean change from baseline (mM).
[Analysis 3.10]
Analysis 3.10. Comparison 3 Deferiprone and DFO in combination versus DFO alone, Outcome 10 Total iron excretion: mean at endpoint (mg/kg/day).
[Analysis 3.11]
Analysis 3.11. Comparison 3 Deferiprone and DFO in combination versus DFO alone, Outcome 11 Adverse events.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Deferiprone dose A versus deferiprone dose B, Outcome 1 Serum ferritin concentration: mean at endpoint (ng/ml).